These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 20534854)

  • 1. CD4 T-cell help programs a change in CD8 T-cell function enabling effective long-term control of murine gammaherpesvirus 68: role of PD-1-PD-L1 interactions.
    Dias P; Giannoni F; Lee LN; Han D; Yoon S; Yagita H; Azuma M; Sarawar SR
    J Virol; 2010 Aug; 84(16):8241-9. PubMed ID: 20534854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD40 engagement on dendritic cells, but not on B or T cells, is required for long-term control of murine gammaherpesvirus 68.
    Giannoni F; Shea A; Inglis C; Lee LN; Sarawar SR
    J Virol; 2008 Nov; 82(22):11016-22. PubMed ID: 18768977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of CD4 T cell changes in murine AIDS is dependent on costimulation and involves a dysregulation of homeostasis.
    Yen MH; Lepak N; Swain SL
    J Immunol; 2002 Jul; 169(2):722-31. PubMed ID: 12097374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.
    Keir ME; Latchman YE; Freeman GJ; Sharpe AH
    J Immunol; 2005 Dec; 175(11):7372-9. PubMed ID: 16301644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.
    Lucas CL; Workman CJ; Beyaz S; LoCascio S; Zhao G; Vignali DA; Sykes M
    Blood; 2011 May; 117(20):5532-40. PubMed ID: 21422469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promotion of a subdominant CD8 T cell response during murine gammaherpesvirus 68 infection in the absence of CD4 T cell help.
    Freeman ML; Roberts AD; Burkum CE; Woodland DL; Blackman MA
    J Virol; 2014 Jul; 88(14):7862-9. PubMed ID: 24789784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo.
    Habicht A; Kewalaramani R; Vu MD; Demirci G; Blazar BR; Sayegh MH; Li XC
    Am J Transplant; 2007 Dec; 7(12):2683-92. PubMed ID: 17924994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens.
    Martin-Orozco N; Wang YH; Yagita H; Dong C
    J Immunol; 2006 Dec; 177(12):8291-5. PubMed ID: 17142723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
    Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
    J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
    Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
    Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells.
    Hu HM; Winter H; Ma J; Croft M; Urba WJ; Fox BA
    J Immunol; 2002 Nov; 169(9):4897-904. PubMed ID: 12391201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition.
    Barber DL; Mayer-Barber KD; Feng CG; Sharpe AH; Sher A
    J Immunol; 2011 Feb; 186(3):1598-607. PubMed ID: 21172867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced CD8 T-cell anti-viral function and clinical disease in B7-H1-deficient mice requires CD4 T cells during encephalomyelitis.
    Phares TW; Stohlman SA; Hinton DR; Bergmann CC
    J Neuroinflammation; 2012 Dec; 9():269. PubMed ID: 23237504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
    Durgan K; Ali M; Warner P; Latchman YE
    Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
    Front Immunol; 2018; 9():1955. PubMed ID: 30214445
    [No Abstract]   [Full Text] [Related]  

  • 17. RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.
    Borkner L; Kaiser A; van de Kasteele W; Andreesen R; Mackensen A; Haanen JB; Schumacher TN; Blank C
    Cancer Immunol Immunother; 2010 Aug; 59(8):1173-83. PubMed ID: 20349059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway.
    Haspot F; Fehr T; Gibbons C; Zhao G; Hogan T; Honjo T; Freeman GJ; Sykes M
    Blood; 2008 Sep; 112(5):2149-55. PubMed ID: 18577709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.
    Arina A; Karrison T; Galka E; Schreiber K; Weichselbaum RR; Schreiber H
    Cancer Immunol Res; 2017 Feb; 5(2):127-136. PubMed ID: 28077434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection.
    Vezys V; Penaloza-MacMaster P; Barber DL; Ha SJ; Konieczny B; Freeman GJ; Mittler RS; Ahmed R
    J Immunol; 2011 Aug; 187(4):1634-42. PubMed ID: 21742975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.